3Spine

Executive Summary

3Spine is a privately-held medical device company headquartered in Memphis, Tennessee, dedicated to advancing spinal care through motion-preserving technology. Founded in 2015, the company has developed the MOTUS system, the first total joint replacement (TJR) implant for the lumbar spine. Unlike traditional spinal fusion, which eliminates motion at the treated segment, MOTUS is designed to replace both the intervertebral disc and facet joints, thereby preserving natural spinal kinematics while alleviating leg and back pain. This innovative approach addresses a significant unmet need in spine surgery, where fusion remains the standard of care despite its limitations in adjacent segment degeneration and restricted mobility. 3Spine's technology has the potential to offer a more physiologic solution for appropriate patients with degenerative disc disease or facet joint pathology. The company operates in the competitive medical device landscape, with a focus on neurosurgery and orthopedic spine markets. As a private entity, 3Spine has not disclosed its total funding or valuation, but its unique product positioning and intellectual property could attract strategic partnerships or acquisition interest from larger spine companies. The success of MOTUS will depend on clinical evidence, regulatory clearance, and market adoption by surgeons. Key upcoming milestones include pivotal clinical trial data, FDA submission, and potential commercialization efforts. While the company faces technical and regulatory risks, its disruptive approach could reshape lumbar spine surgery if proven safe and effective.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance or PMA Submission for MOTUS60% success
• Q2 2027Publication of Pivotal Clinical Trial Results55% success
• Q4 2026Series B or Series C Funding Round70% success